Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06611176
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-23
Brief Title:
Local LevoBupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Local Levobupivacaine for Pain Relief After Endoscopic Submucosal Dissection for Esophageal Lesions a Randomized Controlled Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BESD-RCT
Brief Summary:
Endoscopic submucosal dissection ESD is commonly performed for precancerous lesions in the esophagus Following ESD post-procedural chest pain is seen in many patients Studies have shown that local bupivacaine BP into the residual submucosal layer of the resection wound after gastric ESD could reduce post-procedural pain rates effectively Levobupivacaine LB is equipotent to BP regarding analgesic effects but has a better safety profile No studies have been performed to evaluate the efficacy of LB after esophageal ESD to reduce pain Therefore we want to evaluate the effect on post-procedural pain of local application of LB during esophageal ESD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None